This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of an intensive lifestyle intervention or Metformin to prevent or delay the development of diabetes in a population selected to be at high risk due to the presence of impaired glucose intolerance (IGT). Development of diabetes, defined by the 1997 ADA criteria, was the primary outcome while cardiovascular disease and its risk factors were important secondary outcomes.On the basis of a statistically significant and clinically compelling decrease in the development of diabetes in the lifestyle intervention and the Metformin treated groups (58% and 31% reduction in hazards respectively) compared with the placebo treated group the DPP Data Monitoring Board and NIDDK ended the masked treatment phase of the study August 2001, one year earlier than originally planned.The DPP addressed its primary objective, establishing the efficacy of lifestyle modification and Metformin in decreasing the incidence of diabetes in an ethnically diverse population at high risk for an average of 2.8 years; however, many important issues remained unanswered.The Diabetes Prevention Program Outcomes Study (DPPOS) is a prospective study of the effects of DPP interventions on continued prevention or delay of diabetes, and on preventing or ameliorating its complications, specifically cardiovascular disease and diabetic microangiopathy. The rationale for the overall design is to provide maintenance of therapies found to be effective in DPP, to assess the long-term impacts on diabetes prevention and complications.All participants will be followed for five years, with a total mean follow-up of approximately 9 years from the beginning of DPP.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001032-33
Application #
7718960
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2008-04-01
Project End
2008-05-31
Budget Start
2008-04-01
Budget End
2008-05-31
Support Year
33
Fiscal Year
2008
Total Cost
$14,282
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Chung, Chen-Chih; Pimentel Maldonado, Daniela A; Jor'dan, Azizah J et al. (2018) Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus. J Neurol 265:2267-2276
Kline, Emily R; Seidman, Larry J; Cornblatt, Barbara A et al. (2018) Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res 192:357-363
Simpson, Norah S; Scott-Sutherland, Jennifer; Gautam, Shiva et al. (2018) Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain 159:33-40
Dai, Weiying; Duan, Wenna; Alfaro, Freddy J et al. (2017) The resting perfusion pattern associates with functional decline in type 2 diabetes. Neurobiol Aging 60:192-202
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Irazabal, María V; Abebe, Kaleab Z; Bae, Kyongtae Ty et al. (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32:1857-1865
Hart, Joseph; Novak, Vera; Saunders, Charles et al. (2016) Transcranial Doppler-Based Surrogates for Cerebral Blood Flow: A Statistical Study. PLoS One 11:e0165536
Alfaro, Freddy J; Lioutas, Vasileios-Arsenios; Pimentel, Daniela A et al. (2016) Cognitive decline in metabolic syndrome is linked to microstructural white matter abnormalities. J Neurol 263:2505-2514

Showing the most recent 10 out of 642 publications